INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA under Accelerated Approval Program

PLYMOUTH MEETING - INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious...

Related Keywords

United States ,American ,Jacqueline Shea ,Kim Mcclellan ,Jennie Willson ,Triological Society ,Recurrent Respiratory Papillomatosis Foundation ,American Laryngological Association ,Drug Administration ,Esophageal Association ,Exchange Commission ,European Commission ,Breakthrough Therapy Designation ,Chief Executive Officer ,Broncho Esophageal Association ,Laryngological Association ,Annual Meeting ,Interim Results ,Label Study ,Breakthrough Therapy ,Orphan Drug ,Quarterly Report ,News Publishing ,Markets ,